Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
lunes, octubre 19
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Mirum Pharmaceuticals Inc
MIRM
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$80.14
-2.25
-2.73%
Últ. Act.: Oct 19, 7:19 AM
$80.71
-1.68
-2.04%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Mirum Pharmaceuticals Analyst Price Targets - Benzinga
Mirum Pharmaceuticals Analyst Price Targets
Wall Street analyst price targets and consensus rating for Mirum Pharmaceuticals (MIRM).
Analyst Ratings News
PRO
Stifel Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $156
Stifel analyst James Condulis maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $136 to $156.
Benzinga Newsdesk
PRO
Evercore ISI Group Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $146
Evercore ISI Group analyst Gavin Clark-Gartner maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $135 to $146.
Benzinga Newsdesk
PRO
Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $152
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $137 to $152.
Benzinga Newsdesk
PRO
Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $184
Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $160 to $184.
Benzinga Newsdesk
PRO
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $200
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $195 to $200.
Benzinga Newsdesk
PRO
RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $155
RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $135 to $155.
Benzinga Newsdesk
Crear lista de seguimiento
GRATIS: Haz un seguimiento de acciones y criptomonedas con las mejores alertas de Internet
Haz clic para comenzar
People Also Watch
AbbVie Inc
NYSE:ABBV
$283.8
-%
Amgen Inc
NASDAQ:AMGN
$430.36
-0.5%
Gilead Sciences Inc
NASDAQ:GILD
$155.98
-0.13%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
$502
0.45%
Moderna Inc
NASDAQ:MRNA
$214.99
-1.4%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
$788
-0.35%
Natera Inc
NASDAQ:NTRA
$398
1.15%
argenx SE
NASDAQ:ARGX
$819.98
0.1%
BeOne Medicines Ltd
NASDAQ:ONC
$369.06
-%
Revolution Medicines Inc
NASDAQ:RVMD
$181.5
1.95%
Muestra todas las empresas relacionadas con 10
